Bispecific antibodies (bsAbs) utilize the properties of two antibodies and integrate them for parallel recognition of various antigens or epitopes. Such a “two-target” functionality implies that the interest in their use for therapeutic applications has grown remarkably.
The development and maturity of the bsAb technology stage have made the combination selection of targets a primary aspect of competition. Currently, among the bsAb programs under development, the combination of CD3 and tumor surface targets is the most popular target pair. The new targets of the immune cells are also capable of offering more options in targets combination in the future.
Hot targets
Image Credit: ACROBiosystems
Free samples are available for bsAb hot targets.
CD3 proteins
Features
- Delivers high bioactivity and batch-to-batch consistency
- Bioactivity verified using clinical bispecific antibody
- MALS verified heterodimer
- Comprise several tags and species
Image Credit: ACROBiosystems
Table 1. Source: ACROBiosystems
| Molecule |
Cat. No. |
Species |
Product Description |
Structure |
| CD3E & CD3D |
CDD-H5255 |
HEK293 |
Human CD3 epsilon&CD3 delta Heterodimer Protein, Fc Tag&Fc Tag (MALS verified)New |
|
| CDD-H52Wa |
HEK293 |
Human CD3 epsilon&CD3 delta Heterodimer Protein, Fc,His Tag&Fc,Flag Tag (MALS verified)Hot |
|
| CDD-H82W6 |
HEK293 |
Biotinylated Human CD3 epsilon&CD3 delta Heterodimer Protein, His,Avitag™&Tag Free (MALS verified)Hot |
|
| CDD-H52W1 |
HEK293 |
Human CD3 epsilon & CD3 delta Heterodimer Protein, His Tag&Tag Free (MALS verified)Hot |
|
| CDD-H5258 |
HEK293 |
Human CD3E&CD3D Heterodimer Protein, Llama Fc&Llama Fc, low endotoxin |
|
| CDD-H82F6 |
HEK293 |
Biotinylated Human CD3 epsilon&CD3 delta Heterodimer Protein, Fc,His,Avitag™&Fc,Flag,Avitag™ (MALS verified) |
|
| CDD-H82W0 |
HEK293 |
Biotinylated Human CD3E&CD3D Heterodimer Protein, Fc,His Tag&Fc,Flag Tag, ultra sensitivity (primary amine labeling) (MALS verified) |
|
| CDD-C5259 |
HEK293 |
Cynomolgus CD3E&CD3D Heterodimer Protein, Llama Fc&Llama Fc, low endotoxin |
|
| CDD-C52W4 |
HEK293 |
Cynomolgus CD3 epsilon&CD3 delta Heterodimer Protein, His Tag&Flag Tag (MALS verified) |
|
| CDD-C52W9 |
HEK293 |
Cynomolgus CD3 epsilon&CD3 delta Heterodimer Protein, Fc,His Tag&Fc,Flag Tag (MALS verified) |
|
| CDD-C82W6 |
HEK293 |
Biotinylated Cynomolgus CD3E&CD3D Heterodimer Protein, His,Avitag™&Tag Free (MALS verified) |
|
| CDD-M5219 |
HEK293 |
Mouse CD3 epsilon&CD3 delta Heterodimer Protein, His Tag&Flag Tag (MALS verified) |
|
| CDD-M52W2 |
HEK293 |
Mouse CD3 epsilon&CD3 delta Heterodimer Protein, Fc,His Tag&Fc,Flag Tag (MALS verified) |
|
| CDD-M82W5 |
HEK293 |
Biotinylated Mouse CD3 epsilon&CD3 delta Heterodimer Protein, His,Avitag™&Tag Free |
|
| CDD-R5257 |
HEK293 |
Rat CD3 epsilon&CD3 delta Heterodimer Protein, Llama Fc Tag&Llama Fc Tag (MALS verified) |
|
| CDD-R52D8 |
HEK293 |
Rat CD3 epsilon&CD3 delta Heterodimer Protein, His Tag&Flag Tag (MALS verified) |
|
| CDD-R5259 |
HEK293 |
Rabbit CD3E&CD3D Heterodimer Protein, Llama Fc&Llama Fc, low endotoxin (MALS verified) |
|
| CDD-R52D7 |
HEK293 |
Rabbit CD3 epsilon&CD3 delta Heterodimer Protein, His Tag&Flag Tag (MALS verified) |
|
| MBS-K003 |
|
Human CD3E & CD3D Heterodimer-coupled Magnetic Beads |
|
PD-1/PD-L1 proteins
Features
- High bioactivity verified
- High purity and homogeneity
- Different tags and species
Image Credit: ACROBiosystems
CD47 proteins
Features
- High bioactivity verified
- High purity and homogeneity
- Ideal for immunization and inhibitor
Image Credit: ACROBiosystems
Full-length CD20 proteins
Features
- Superior bioactivity verified
- Authentic conformation
- Unique nanodisk technology
Image Credit: ACROBiosystems
Bioactivity analysis of bispecific antibody
It is important to perform characterization and pharmacokinetic (PK)/PD assessment. Quality factors such as antigen specificity; affinity and on- and off-rates; avidity (for bispecific antibodies that target two molecules on the same cell); potency; process-related impurities such as aggregates, fragments, and homodimers; stability; and half-life may affect pharmacology and should be analyzed.
However, bispecific antibodies may occur as a blend of biologically active and inactive forms. Hence, it is significant to determine the bispecific antibody form(s) that is pharmacologically relevant to PK/PD test and make confirmed assays that can evaluate the suitable form(s) accordingly.
The synergetic effect caused by BsAb makes the dosage relatively low and hence requires a more sensitive assay for analysis.
Case study 1: Antigen-antibody affinity
Figure 1. Immobilized Human CD3E&CD3D Heterodimer Protein, His Tag&Tag Free (Cat. No. CDD-H52W1) at 2 μg/mL, add increasing concentrations of Bispecific T cell Engager (CD3 X BCMA) and then add Biotinylated BCMA Fc, Avitag (Cat. No. BC7-H82F0) at 0.2 μg/mL. Detection was performed using HRP-conjugated streptavidin with a sensitivity of 4 ng/mL. Image Credit: ACROBiosystems
Case study 2: FcR-antibody affinity
Figure 2. Binding assay between bsAb and Fc receptor. Image Credit: ACROBiosystems
Case study 3: Intact assay of bsAb
Figure 3. Immobilized Human OX40 Protein, His Tag (MALS verified) (Cat. No. OX0-H5224) at 2 μg/mL, add increasing concentrations of CTLA-4 x OX40 bispecific antibody in 50% Human serum and then add Biotinylated Human CTLA-4, Fc, Avitag (Cat. No. CT4-H82F3) at 0.2 μg/mL. Detection was performed using HRP-conjugated streptavidin with sensitivity of 4 ng/mL (Intact assay). Image Credit: ACROBiosystems
Methodology validation
Table 2. Source: ACROBiosystems